SPY308.08+2.53 0.83%
DIA257.85+2.58 1.01%
IXIC9,608.38+56.33 0.59%

Morgan Stanley Downgrades Kaleido Biosciences to Equal-Weight, Announces $8 Price Target

Morgan Stanley analyst Matthew Harrison downgrades Kaleido Biosciences (NASDAQ:KLDO) from Overweight to Equal-Weight and announces $8 price target.

Benzinga · 05/21/2020 10:06

Morgan Stanley analyst Matthew Harrison downgrades Kaleido Biosciences (NASDAQ:KLDO) from Overweight to Equal-Weight and announces $8 price target.